# HD21 (NCT02661503)

> HD21 for Advanced Stages

No report yet. It can be ordered.

- Drugs tested: BrECADD
- Indication: first-line advanced-stage classical Hodgkin lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02661503
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: University of Cologne
- Conditions: Classical Hodgkin Lymphoma
- Interventions: Bleomycin; Etoposide; Doxorubicin; Cyclophosphamide; Vincristine; Procarbazine; Prednisone; Brentuximab Vedotin; Dacarbazine; Dexamethasone
- Enrollment: 1500
- Primary outcome: Progression Free Survival
- Primary outcome: Treatment Related Morbidity

## Some of the questions raised in the 40 most recent indexed sources

_Automated from the 40 newest of 130 indexed sources (May 2025 – Nov 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether PET-adapted BrECADD or nivolumab-AVD should be chosen for young adults, with no head-to-head comparison
- Whether PET-guided BrECADD should extend to early-stage unfavorable or bulky disease with B symptoms
- How often BrECADD causes persisting peripheral neuropathy in routine practice compared with HD21

## Indexed commentary on HD21 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 80 posts on X
- 31 YouTube videos
- 17 podcast episodes
- 2 videos on X

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=hd21-nct02661503

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02661503", "email": "<work email>"}; the inbox owner confirms by the emailed link.
